Point72 Asia Singapore Pte. Ltd. Makes New Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Point72 Asia Singapore Pte. Ltd. bought a new stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,854 shares of the company’s stock, valued at approximately $87,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.06% of Vigil Neuroscience as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after acquiring an additional 95,276 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Vigil Neuroscience in the 2nd quarter valued at about $26,000. Renaissance Technologies LLC lifted its position in shares of Vigil Neuroscience by 19.2% in the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares in the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after purchasing an additional 166,442 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in Vigil Neuroscience during the second quarter valued at approximately $5,940,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Trading Up 1.2 %

Shares of NASDAQ:VIGL opened at $3.44 on Friday. The stock has a market capitalization of $136.40 million, a PE ratio of -1.62 and a beta of 1.95. Vigil Neuroscience, Inc. has a 1 year low of $2.47 and a 1 year high of $9.24. The firm has a fifty day moving average price of $3.51 and a 200 day moving average price of $3.53.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. On average, sell-side analysts forecast that Vigil Neuroscience, Inc. will post -2.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on VIGL. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a research note on Wednesday, August 14th. Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, July 11th. Finally, Guggenheim cut their price target on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Vigil Neuroscience has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.